These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69. 5-Lipoxygenase activating protein (FLAP) dependent leukotriene biosynthesis inhibition (MK591) attenuates Lipid A endotoxin-induced inflammation. Fang WF; Douglas IS; Wang CC; Kao HC; Chang YT; Tseng CC; Huang KT; Chang HC; Lin MC PLoS One; 2014; 9(7):e102622. PubMed ID: 25025775 [TBL] [Abstract][Full Text] [Related]
70. Soluble epoxide hydrolase inhibitors and cardiovascular diseases. Wang ZH; Davis BB; Jiang DQ; Zhao TT; Xu DY Curr Vasc Pharmacol; 2013 Jan; 11(1):105-11. PubMed ID: 22303912 [TBL] [Abstract][Full Text] [Related]
71. Soluble epoxide hydrolase: A potential target for metabolic diseases. He J; Wang C; Zhu Y; Ai D J Diabetes; 2016 May; 8(3):305-13. PubMed ID: 26621325 [TBL] [Abstract][Full Text] [Related]
72. Synthesis and structure-activity relationship studies of novel dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase. Meirer K; Rödl CB; Wisniewska JM; George S; Häfner AK; Buscató EL; Klingler FM; Hahn S; Berressem D; Wittmann SK; Steinhilber D; Hofmann B; Proschak E J Med Chem; 2013 Feb; 56(4):1777-81. PubMed ID: 23356879 [TBL] [Abstract][Full Text] [Related]
73. Investigation of the binding mode of 1, 3, 4-oxadiazole derivatives as amide-based inhibitors for soluble epoxide hydrolase (sEH) by molecular docking and MM-GBSA. Karami L; Saboury AA; Rezaee E; Tabatabai SA Eur Biophys J; 2017 Jul; 46(5):445-459. PubMed ID: 27928588 [TBL] [Abstract][Full Text] [Related]
74. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Inceoglu B; Jinks SL; Schmelzer KR; Waite T; Kim IH; Hammock BD Life Sci; 2006 Nov; 79(24):2311-9. PubMed ID: 16962614 [TBL] [Abstract][Full Text] [Related]
75. Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease. Antoniu SA Expert Opin Ther Targets; 2014 Nov; 18(11):1285-92. PubMed ID: 25213852 [TBL] [Abstract][Full Text] [Related]
76. The Inhibition Activity of Natural Methoxyflavonoid from Kim JH; Han KS; Lee ES; Kim YG; Kim YI; Cho BO; Lee IS Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673942 [TBL] [Abstract][Full Text] [Related]
77. Inhibition of soluble epoxide hydrolase alleviated atherosclerosis by reducing monocyte infiltration in Ldlr(-/-) mice. Li D; Liu Y; Zhang X; Lv H; Pang W; Sun X; Gan LM; Hammock BD; Ai D; Zhu Y J Mol Cell Cardiol; 2016 Sep; 98():128-37. PubMed ID: 27496380 [TBL] [Abstract][Full Text] [Related]
78. Recent advances for FLAP inhibitors. Pettersen D; Davidsson Ö; Whatling C Bioorg Med Chem Lett; 2015 Jul; 25(13):2607-12. PubMed ID: 26004579 [TBL] [Abstract][Full Text] [Related]
79. 5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis. Plante H; Picard S; Mancini J; Borgeat P Biochem J; 2006 Jan; 393(Pt 1):211-8. PubMed ID: 16144515 [TBL] [Abstract][Full Text] [Related]
80. Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors. Takai K; Chiyo N; Nakajima T; Nariai T; Ishikawa C; Nakatani S; Ikeno A; Yamamoto S; Sone T Bioorg Med Chem Lett; 2015 Apr; 25(8):1705-1708. PubMed ID: 25800114 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]